跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Acetylcysteine amide
首页
药物
Acetylcysteine amide
Experimental
Small Molecule
Acetylcysteine amide
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
技术标识符
化学式
C
5
H
10
N
2
O
2
S
CAS 编号
38520-57-9
UNII ID
4N69717RKW
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
METHODS OF MAKING DEUTERIUM-ENRICHED N-ACETYLCYSTEINE AMIDE (D-NACA) AND (2R,2R')-3,3' -DISULFANEDIYL BIS(2-ACETAMIDOPROPANAMIDE) (DINACA) AND USING D-NACA AND DINACA TO TREAT DISEASES INVOLVING OXIDATIVE STRESS
EP 3534890 A4
申请人: NACUITY PHARMACEUTICALS INC
优先权: 2017
CN
EP
US
WO
6 件公开
TREATMENT OF RETINITIS PIGMENTOSA WITH N-ACETYLCYSTEINE AMIDE
EP 3214934 A4
申请人: UNIV JOHNS HOPKINS
优先权: 2014
CN
EP
US
5 件公开
N-ACETYLCYSTEINE AMIDE (NAC AMIDE) FOR THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH OXIDATIVE STRESS
US 2009234011 A1
申请人: GOLDSTEIN GLENN A
优先权: 2006
US
5 件公开
US 8993627 B2
申请人: SENTIENT LIFESCIENCES INC
优先权: 2013
US
5 件公开
TREATMENT OF CYSTINOSIS
EP 4161498 A1
申请人: NACUITY PHARMACEUTICALS INC
优先权: 2020
CN
EP
WO
3 件公开
TREATMENT OF RETINITIS PIGMENTOSA AND RETINITIS PIGMENTOSA ASSOCIATED WITH USHER SYNDROME WITH N-ACETYLCYSTEINE AMIDE
US 20260014102 A1
申请人: NACUITY PHARMACEUTICALS INC
优先权: 2025
US
3 件公开
N-Acetylcysteine Amide (NACA) and (2R,2R′)-3,3′ disulfanediyl BIS(2-acetamidopropanamide) (DINACA) for the prevention and treatment of radiation dermatitis and skin lightening, skin whitening and skin improvement
US 12458608 B2
申请人: NACUITY PHARMACEUTICALS INC
优先权: 2019
CN
US
2 件公开
N-Acetylcysteine Amide Tablets Inhibit Reduction in Vision in Patients with Usher Syndrome Associated Retinitis Pigmentosa
US 20260083688 A1
申请人: NACUITY PHARMACEUTICALS INC
优先权: 2024
US
WO
2 件公开
N-Acetylcysteine Amide (Nac Amide) for Treatment of Oxidative Stress Associated with Infertility
US 2008200548 A1
申请人: GOLDSTEIN GLENN A
优先权: 2006
US
2 件公开
Compositions And Methods For Amelioration And Prevention Of Drug-Induced Toxicity
US 2015080348 A1
申请人: MOGRABI JOSEF
优先权: 2014
US
2 件公开
Methods of Making Deuterium-Enriched N-Acetylcysteine Amide (D-NACA) and (2R,2R)-3,3-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress
US 2024217927 A1
申请人: NACUITY PHARMACEUTICALS INC
优先权: 2024
US
2 件公开
US 2023373913 A1
申请人: NACUITY PHARMACEUTICALS INC
优先权: 2023
US
第 1 / 3 页
上一页
下一页
药物
反馈